01 · The Reframe
RBQM alerts come late. Issues have been building since startup.
ArcheMedX is sponsoring Fierce Biotech Week in Boston.
CEO Joel Selzer is joining the Integrated Risk Mitigation panel Tuesday at 4:50 PM
If you're attending, schedule a 1:1 below
Trial risk is a human‑performance signal before it becomes a data signal.
Most programs catch execution risk after it surfaces. There's an earlier signal. Most operating models aren't built to read it.
The Reframe
RBQM looks back. Readiness looks ahead.
By the time deviations and delays surface in your monitoring data, the underlying cause has been building since site initiation. The window to act has already closed. Readiness signals appear earlier — during the SIV — when there's still time to intervene.
Leading Indicator
Readiness signal appears at SIV
Confidence and comprehension gaps are measurable before first patient in — when corrective action is still possible.
Lagging Indicator
Typical risk signals appear after FPI
Protocol deviations, query rates, and enrollment delays surface downstream — after the cause has compounded.
The Insight
Risk begins as a human problem, not an operational one.
ICH E6(R3) raises the bar: verify readiness, not training completion. A site team that has completed required training may still lack the confidence and comprehension to execute the protocol correctly. That gap is measurable — and predictive.
02 · The Insight
Risk begins as a human problem. ICH R3 requires trial readiness.
03 · The Shift
Readiness measured at startup, predicts risk before 1st patient.
04 · Ready
Better-prepared sites. Earlier signals. Both powered by Ready.
The Ready Platform
The leading indicator your RBQM program is missing.
Ready is a behavioral science-based readiness intelligence platform that does two things simultaneously: it delivers more effective training — improving how teams understand and execute the protocol — while generating the site readiness signals your program needs before first patient in.
Confidence-Based Assessment (CBA) captures not just what site staff know, but how confident they are in that knowledge. The combination predicts performance far more accurately than completion data alone.
Ready converts engagement, comprehension, and confidence signals into a Site Readiness Score, before first patient in.
"It's almost not worth funding programs that aren't powered by Ready…"Executive Director · Top-20 Pharma
Research
A decade of research. 300,000+ clinical professionals. One consistent finding.
Ready is built on evidence, not intuition. The behavioral and learning sciences have spent decades establishing what actually predicts human performance: not whether training was completed, but the quality of what was learned, how confidently it's held, and how reliably it transfers to practice under pressure.
ArcheMedX has applied that body of research to the specific context of clinical trial site readiness. The underlying science spans cognitive psychology, self-efficacy theory, metacognition, and behavior change. The dataset behind Ready reflects more than 100 million modeled behavioral data points generated by over 300,000 clinical professionals across 90+ countries.
The finding is consistent: confidence calibration during training is a leading indicator of downstream execution risk. Sites that complete passive training are not necessarily sites that are ready. The gap between the two is measurable before first patient in. Ready is proven to increase trial performance and mitigate study risks.
Latest Research Article
The Earliest Warning Sign: Measuring Risk in Clinical Trials by McGowan & Ritch - Applied Clinical Trials
Let's Connect During Fierce Biotech Week
We'll walk through your program and show you where the readiness signal appears — and what you can act on before first patient in.
Let's connect for a conversation while we are in Boston